Novacyt (LON:NCYT – Get Free Report) issued its earnings results on Wednesday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Novacyt had a negative net margin of 103.08% and a negative return on equity of 96.44%.
Novacyt Price Performance
Novacyt stock traded down GBX 2.09 during mid-day trading on Thursday, reaching GBX 39.91. 73,709 shares of the company’s stock traded hands, compared to its average volume of 174,527. Novacyt has a 12-month low of GBX 26.60 and a 12-month high of GBX 86. The company has a quick ratio of 4.46, a current ratio of 4.74 and a debt-to-equity ratio of 44.74. The company has a market cap of £28.94 million, a price-to-earnings ratio of -1.25 and a beta of 1.11. The stock has a 50 day moving average of GBX 41.85 and a two-hundred day moving average of GBX 39.13.
Novacyt Company Profile
The Company is divided into three business segments:
Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.
Featured Articles
- Five stocks we like better than Novacyt
- First Watch’s Growth Story Meets a Reality Check
- Down 50% and Climbing Again: 3 AI Stocks Rebuilding After Brutal Pullbacks
- Micron’s Earnings Reveal Why the AI Memory Boom May Last Longer
- Hobby Boom or Travel Bust? Here Are 3 Stocks to Ride the Trend
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
